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Abstract
Medicine use in pregnancy is extremely common, but there are significant
knowledge gaps surrounding the safety, dosage and long-term effects of
drugs used. Pregnant women have been purposively excluded from clinical
trials of the majority of treatments for conditions that may occur concurrently
with pregnancy. There is minimal information on the pharmacokinetics of
many existing treatments and no systematic capture of long-term outcome
data to help inform choices. Treatments commonly used in pregnancy are
thus often old and untested, not optimised in dose, and prescribed off-label
without adequate safety information. In addition, there has been a
staggering lack of investment in drug development for obstetric conditions
for decades. This is a major public health concern, and pregnancy
complications are the leading cause of mortality in children under five years
old globally, and health in pregnancy is a major determinant of women’s
long-term health and wellbeing. There is an acute need for adequate
investment and legislation to boost inclusion of pregnant women in clinical
studies, capture high-quality information on medication use in pregnancy in
general, and encourage new medicinal product development for obstetric
conditions.
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Introduction
In high-income countries, four out of five pregnant women are 
prescribed one or more medications in pregnancy1, and even 
higher levels of pregnant women self-medicate with over-the- 
counter preparations2. Medicines may be taken for a wide 
range of acute or non-acute indications, as outlined in Box 1. 
However, more than 98% of drugs have insufficient pharma-
cokinetic or safety data to guide dosing in women who are 
pregnant or breastfeeding3,4.
Box 1. Potential indications for medicine use in pregnancy 
and examples of types of treatments
Indication Examples of treatments
Medical conditions that 
predate, develop during, or 
are recognised for the first 
time in pregnancy
Asthma treatments, treatments 
for thyroid disorders, anti-
hypertensives, insulin, anti-
epileptics, anti-retrovirals
Psychiatric conditions that 
predate, develop during, or 
are recognised for the first 
time in pregnancy
Anti-depressants and 
anxiolytics, mood stabilisers
Replacement therapies Methadone, nicotine 
replacement
Symptoms caused by or 
exacerbated by pregnancy
Anti-emetics, laxatives, 
antacids
Intercurrent illnesses Anti-infectives, analgesics
Vaccinations Pertussis, influenza
Fertility and miscarriage 
treatments
Clomiphene, progesterone, 
low-molecular-weight heparin
Nutritional supplementation 
and vitamins
Iron supplements, folic acid
Prevention and treatment of 
obstetric conditions (pre-
term labour, pre-eclampsia, 
fetal growth restriction, 
gestational diabetes)
Aspirin, progestagens, anti-
hypertensives, tocolytics, 
hypoglycaemic agents
Treatments to optimise the 
health of the newborn
Antenatal corticosteroids, 
magnesium sulphate
Very few drugs have been optimised for use by pregnant 
mothers, and there has been chronic under-investment both 
in new drug development and in clinical trials of established 
therapies in pregnancy5,6. Even when teratogenic effects of medi-
cations are recognised (as in the case for sodium valproate), 
messages about risk may not be delivered effectively to women 
of reproductive age7 and it can take decades for legislation to 
be enacted to support safe prescribing8. Research into medica-
tion in pregnancy is complicated by a number of factors that 
we outline below. Nevertheless, technologies are available 
that, if appropriately applied, have the potential to greatly 
improve the delivery of safe and efficacious medications in 
pregnancy.
Gaps in knowledge on medications in pregnancy
It is generally expected that the efficacy, optimal dose and any 
short-term harmful effects of medications will be determined 
in the pre-clinical and clinical trial phases of drug develop-
ment. However, involvement of pregnant participants in drug 
studies has been negligible over the past decades and this is due 
to purposive exclusion because of teratogencity risks or other 
harmful effects on the fetus. Thus, safety information is rarely 
available for medications that are used in pregnancy5. Physi-
ological changes in pregnancy significantly affect the phar-
macokinetics of prescribed drugs (Box 2) and pregnancy can 
alter the course and symptomology of illnesses. The effective-
ness of drugs may therefore be very different in pregnancy than 
without pregnancy5. The scale of the evidence gap for appro-
priate dosing of medications in pregnant women was shown 
in a 2014 report that found that only 1.3% of pharmacoki-
netic studies were performed in pregnancy3. The fact that less 
than 10% of these studies were industry-funded is evidence of 
the lack of engagement from pharmaceutical companies to 
provide these data and of the lack of incentives for them to do 
so. Even when changes in pharmacokinetics are recognised, 
there is a lack of studies describing how these impact outcomes 
of the mother and baby9 and so the clinical implications of phar-
macokinetic changes are unknown. Inadvertent under-treatment 
may contribute to maternal and perinatal morbidity associated 
with medical conditions in pregnancy.
Box 2. Physiological changes in pregnancy and potential 
effects on pharmacokinetics (as reviewed in 10)
Physiological change in 
pregnancy
Potential effect on 
pharmacokinetics of drugs
↓ gastric emptying/small 
bowel motility
↑ time to reach peak levels
↑ gastric pH ↓ absorption
↑ vascularity and oedema 
respiratory mucosa
↑ absorption of inhaled drugs
↑ minute ventilation ↓ protein binding due to 
respiratory alkalosis 
↑ total body water, blood 
volume and capillary 
hydrostatic pressure
↑ volume of distribution of 
hydrophilic drugs
↑ glomerular filtration rate ↑ renal clearance
↓ serum albumin ↑ active fraction of drug
↑ CYP450 and ↑ UGT activity ↑ metabolism
In addition to differing pharmacokinetics, a key consideration is 
the potential effect of treatments on the baby. Although genotox-
icity, non-clinical reproduction and embryo-fetal developmental 
toxicity studies are standard during the development of most 
drugs, variations in species-specific effects can limit the ability of 
pre-clinical studies to predict human teratogenesis5. Deliber-
ate exclusion of pregnant women from clinical trials of medici-
nal products means that phase 2 or 3 trial data in pregnancy are 
virtually non-existent for drugs that are not one of the hand-
ful of agents designed for a specific obstetric indication. This 
has two important implications for the care of pregnant women. 
First, a large number of medications have contraindications 
or special warnings because they have not been sufficiently 
Page 3 of 8
F1000Research 2019, 8(F1000 Faculty Rev):911 Last updated: 20 JUN 2019
studied in pregnancy, limiting the availability of potentially 
effective treatments to pregnant women. The teratogenic risk 
of 168 of 172 medications approved by the US Food and 
Drug Administration (FDA) between 2000 and 2010 was found 
to be undetermined, and no data about the risk in pregnancy 
were available for 126 of them (73%)4. This means that preg-
nant women may be unnecessarily denied the opportunity to 
receive medicines that could improve their health or the health 
of their baby. Second, establishing the safety of medications is 
nearly exclusively dependent on data collected post-authorisation 
from pregnant women who are inadvertently exposed or in whom 
the risks of stopping treatment are perceived to outweigh any 
potential risks to the baby11.
Challenges in pharmacovigilance
A common source of post-authorisation safety data on medicines 
in pregnancy consists of reports from pregnancy exposure regis-
tries. These have variously been established by pharmaceutical 
companies, academic groups and regulatory authorities. They 
have been used to provide reassurance that certain medications 
are not major teratogens and to identify signals of teratogenic-
ity that require further investigation12. However, although they 
may detect signals of high-risk teratogenesis (where around 
25% of exposed babies are affected), they are generally under-
powered to investigate moderate teratogenicity (for example, 
a 2- to 10-fold increase in risk)11. Numbers of participants are 
limited by low levels of enrolment, which is voluntary, and loss 
to follow-up of registered participants. For example, none of 
the five prospective pregnancy registries sponsored by the 
pharmaceutical company GlaxoSmithKline (Brentford, UK) 
achieved enrolment of 1000 pregnancies in the first 10 years 
of medication marketing, the number considered by the 
European Committee for Medicinal Products for Human Use to 
be representative of widespread exposure13. Lack of an untreated 
comparator group can also be problematic, making it difficult 
to distinguish the effects of a treatment for a disease from the 
effect of the disease process itself12.
In order to more fully determine risks and benefits of medica-
tions in pregnancy, large and complex datasets are required. 
Pregnant women take medications for a variety of reasons. 
A proportion of women who become pregnant are already on 
treatment for pre-existing medical conditions, and pregnancy 
symptoms (such as indigestion or nausea and vomiting), concur-
rent illnesses or infections, and obstetric complications (such as 
pre-eclampsia, intrahepatic cholestasis of pregnancy or pre-
term labour) can precipitate new medicine use. The range of 
indications for treatment means that, although prescriptions are 
common, use of individual drugs can be comparatively rare14, 
necessitating large and diverse data sources to study treatment 
effects5,15. Furthermore, many over-the-counter remedies used 
by pregnant women are not routinely recorded. Accurate infor-
mation about pregnancy exposures and potential confounding 
factors (including other medicine use) is required to allow 
appropriate risk assessment.
A further complexity is the large number of effects that medi-
cations can have. Teratogenesis is often perceived as being 
synonymous with structural malformations, but pregnancy 
medications have a broad range of potential effects in addition 
to birth defects, and these may vary depending on the drug, the 
dose and the period of exposure16. Potential impacts include 
increasing rates of miscarriage, stillbirth, fetal growth perturba-
tions, and pre-term birth. Evaluation of pregnancy treatments 
thus needs to be broad, include women whose pregnancies have 
not continued past the first trimester (to capture effects on early 
pregnancy complications and miscarriage), and be of suffi-
cient scale to recognise rare but serious events such as stillbirth. 
Methods should be sufficiently sensitive to detect severe disabili-
ties but also more subtle effects. For example, drugs may cause 
neurodevelopmental disability but also have effects on behav-
iour and educational attainment which may not be captured in 
standard medical records. Long-term follow-up is essential as 
adverse effects may not be recognised until adulthood or beyond 
or indeed until the second generation. For example, diethyl-
stilboestrol increased the risk of vaginal adnenocarcinoma 
in in utero–exposed offspring and has been associated with 
health effects in subsequent generations17.
Opportunities for advancing knowledge
Although study of medicines in pregnancy is challenging, bar-
riers should not be seen as insurmountable, and advances in 
methodology provide opportunities for new knowledge. Pre-
clinical studies of the safety profile of medications should form 
the basis of any initial studies of any new agent that has the 
potential to be used in pregnancy5. Recommendations regard-
ing the species used in drug safety testing are currently lacking. 
However, as there are huge interspecies differences in both 
placentation and duration of gestation, guidelines are needed to 
ensure that safety testing regarding relevance to human preg-
nancy is optimised. Pre-clinical testing should also ideally 
include follow-up of an entire generation through a complete 
reproductive cycle to capture potential effects on offspring.
New laboratory techniques can provide additional insights 
into pharamcokinetics and mechanisms. Use of xenografts of 
human tissue in rodents has allowed effects of drugs on specific 
tissues to be studied in a more physiological manner than in 
in vitro studies18. Cell and tissue culture methods, placental per-
fusion methods19 and recently reported organoids20 have the 
potential to elucidate placental transfer, metabolism and endo-
crine function, and the effects of drugs on these. “Organ on a 
chip” models may be useful to further explore the maternal and 
fetal contributions, and computational models can be used for 
simulations and data integration16.
Studies involving pregnant women are feasible and necessary 
to close the evidence gap on pharmacokinetics for medications 
in pregnancy. Indeed, there are compelling arguments that rou-
tine exclusion of pregnant women from drug research is unethi-
cal, and responsible inclusion should be mandatory21. Draft 
guidance from the FDA suggests that pregnant women may be 
included in pharmacokinetic studies if (i) there are sufficient data 
from pre-clinical and clinical studies (including non-pregnant 
women) to assess the potential risk to pregnant women and 
fetuses and (ii) the potential risk is minimal and the purpose 
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of the research is to gather important information that cannot 
be otherwise obtained22. Opportunistic study designs involve 
women who are already on treatment, thus separating the 
decision to initiate treatment from the decision to participate in 
a study. This helps avoid concerns over the ethics of exposing 
mothers and babies to unknown risks for the purpose of research5. 
In longitudinal designs, best suited for medications taken over 
a long period of time, women can serve as their own controls 
with samples taken at different gestational time points. It is 
also possible to involve pregnant women who will not benefit 
from the medicine under investigation in pharmacokinetic stud-
ies by restricting administration to a very brief period and using 
different groups of participants to determine drug dynamics 
in different trimesters and post-partum.
Potential for improving knowledge around pregnancy pre-
scribing lies in the exploitation of health data collected for 
clinical or administrative purposes. Population-based birth 
registers, such as those of the Nordic countries, have been a rich 
source of information on drug safety in pregnancy23. Recording 
of all live births and stillbirths within the region covered by the 
registry is mandatory, and registers contain basic information 
on the mother, father and neonate. Linkage through the unique 
personal identity number to other databases can provide data 
on prescribed medications as well as health, education and 
social conditions. A limitation, however, is that not all registers 
capture spontaneous pregnancy losses and induced terminations 
of pregnancy13. Other sources of routinely collected data include 
medical record databases, such as the UK Clinical Practice 
Research Datalink24 containing de-identified patient data from 
primary care linked to other health datasets, representative 
samples of the population, and administrative databases, such as 
those of health insurers25.
Advances in the field of medical informatics mean that there 
has been expansion in the amount, depth and variety of health-
related data collected, alongside increased computational capa-
bility to effectively perform analyses across large datasets26. 
Research questions can now be successfully interrogated across 
multiple databases27. Development of large networks of obser-
vational databases with billions of data points has the potential 
to overcome challenges of limited sample size and lack of 
power28. Appropriate design, methodology and sophisticated 
analysis techniques are, however, essential to account for 
heterogeneity between data sources and for missing and incor-
rect data and to control for important confounders, particularly 
confounding by indication26,29. Further advances are conceiv-
able through supplementation of coded data with information 
obtained from unstructured or ‘free text’ of medical records using 
automated data extraction techniques30, integration of data 
from personal devices and wearable technologies29, and ‘crowd 
sourced’ pharmacoepidemiology through analysis of data 
from social media platforms31. Success depends on coherent 
approaches with considerable infrastructure and investment and 
on remaining cognisant of regulations and privacy concerns to 
ensure public confidence in data use and reuse.
Policy and centralised support for research into medication in 
pregnant women will be key to capitalising on opportunities to 
improve prescribing in pregnancy. In many countries, the average 
maternal age and rates of obesity have risen and both increases 
are associated with a growing burden of co-morbidities and 
pregnancy complications requiring medication. On a global scale, 
maternal conditions are the leading cause of mortality in children 
under five32 and are a major determinant of women’s health and 
wellbeing. Therefore, investment to develop new treatments for 
pregnant women and to optimise existing medications is desper-
ately needed. The dearth of medicinal product development for 
pregnancy conditions was demonstrated in a 2009 report which 
showed that only 17 drugs were under active development for 
maternal health indications33. This represented less than 3% 
of the cardiovascular drug development pipeline and was 
less than for a single rare disease like amyotrophic lateral 
sclerosis (34 drugs in development). Regulatory frameworks 
governing medicines for children in Europe and the US have 
been successful in boosting paediatric drug development, 
paediatric clinical trials, and information on paediatric 
medications34,35. In the US, the Treating for Two initiative 
of the Centers for Disease Control and Prevention aims to 
improve both the evidence base and guidance for safer medi-
cation use in pregnancy to inform decision making36 while 
the Obstetric-Fetal Pharmacology Research Centers Network 
supported by the National Institute of Child Health and Human 
Development aims to improve the understanding of obstetric 
pharmacokinetics and pharmacodynamics through non-clinical, 
clinical and pharmacokinetic and pharmacogenetic studies37. 
However, clinical studies in pregnancy relating to drug devel-
opment, dosing and effectiveness are still a rarity. A 2013 study 
found that only five of 558 USA industry-sponsored drug 
trials were specifically designed for pregnant women, and preg-
nant women were excluded from 95% of phase IV trials38. 
A 2016 systematic review reported that only 0.32% of all active 
registered clinical trials of medicinal products were preg-
nancy drug trials, a tiny minority of those (6%) had a specific 
primary outcome relating to maternal or fetal health, and even 
fewer (4.4%) included pre-planned pharmacokinetics39. Without 
legislative incentives or mandate, pharmaceutical companies 
are likely to remain unwilling to engage in research for preg-
nant women, and academic institutions and researchers may 
remain cautious of doing so.
Conclusions
There is an acute need to provide women with appropriate infor-
mation to judge the risks and benefits of treatment whether 
that is pre-pregnancy (in consideration of an unanticipated 
or planned pregnancy), in pregnancy or when breastfeeding. 
Medicine use in pregnancy is ubiquitous. Studies consistently 
show that the majority of pregnant women are prescribed one 
or more medications in pregnancy, rates are 50 to 80% depend-
ing on the setting, and when over-the-counter treatments are 
included rates approach 100%1,40–43. Data from the US show 
that woman are prescribed an average of 2.6 medications during 
pregnancy41, and a study from Italy estimates this figure to be 
4.6 medications per pregnant woman44. Both mothers and 
clinical care givers overestimate the teratogenic risks of medi-
cations and may err on the side of caution in the absence of 
available and clear safety data45. This denies women appropri-
ate therapy, and inadequate maternal treatment of disease can 
jeopardise both the mother’s and the baby’s wellbeing. On the 
other hand, the vast majority of medications currently in use 
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have not been studied in a way that would reveal moderate 
teratogenic risks, let alone effects on miscarriage, or more 
subtle effects on long-term outcomes. A presumption of safety 
means that effects of even well-established therapies remain 
unmeasured. Every healthcare provider should discuss the 
implications to pregnancy from medications that they prescribe 
to women of (or soon to be of) reproductive age. Healthcare 
providers and women should also be cognisant of the uncer-
tainties in the evidence. Adequate investment and policy are 
needed to improve knowledge about pregnancy prescribing, 
increase public confidence and promote industry engagement 
to develop much-needed new treatments for obstetric condi-
tions. Lack of advancement in this area is unacceptably failing 
women and their families.
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